Welcome to our dedicated page for CONTEXTLOGIC HOLDINGS news (Ticker: LOGC), a resource for investors and traders seeking the latest updates and insights on CONTEXTLOGIC HOLDINGS stock.
ContextLogic Holdings Inc. reports developments as a publicly traded business ownership platform focused on acquiring and building a portfolio of niche, competitively advantaged, long-duration businesses. News about ContextLogic centers on the completed acquisition of US Salt, operating and financial results, acquisition strategy, cash and investment resources, and the company’s evolution into a portfolio ownership model.
Company updates also cover governance and capital-structure matters, including board appointments, audit committee membership, shareholder voting, Delaware reorganization actions, strategic investment arrangements, and securities registration matters. The recurring themes are portfolio ownership, acquisition execution, operating efficiency, and public-company governance.
LogicBio Therapeutics, a clinical-stage genetic medicine company based in Lexington, MA, announced that its CEO, Fred Chereau, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET on September 13. The company focuses on gene editing and delivery platforms, including GeneRide for precise gene insertion and sAAVy for optimizing gene delivery.
LogicBio Therapeutics (Nasdaq: LOGC) reported Q2 2021 financial results with revenues of $0.8 million, down from $1.0 million YoY. R&D expenses increased to $7.3 million from $5.9 million, contributing to a net loss of $10.5 million or $0.33 per share. The company highlighted the dosing of the first patient in the SUNRISE trial for LB-001, aimed at treating methylmalonic acidemia (MMA). Strategic partnerships with Daiichi Sankyo and CANbridge Pharmaceuticals were formed, enhancing its GeneRide and sAAVy platforms.
LogicBio Therapeutics (Nasdaq:LOGC) announced that CEO Frederic Chereau will participate in a virtual panel on Delivery and Durability of Genetic Medicines at the William Blair Biotech Focus Conference 2021.
The event is scheduled for July 15, 2021, at 10:00 a.m. ET. LogicBio is a clinical-stage company focused on gene editing and delivery platforms aimed at treating rare diseases.
Their platforms include GeneRide™ for precise gene insertion and sAAVy™ for optimized gene delivery.
LogicBio Therapeutics (Nasdaq:LOGC) announced the first patient has been dosed with LB-001, a gene editing therapy for methylmalonic acidemia (MMA) in the SUNRISE Phase 1/2 clinical trial. Conducted at Monroe Carell Jr. Children's Hospital at Vanderbilt, this marks a key step in addressing MMA, a rare genetic disorder affecting 1 in 50,000 newborns. The trial aims to evaluate LB-001's safety and tolerability in pediatric patients aged 3-12, with future enrollment for infants as young as 6 months. LogicBio expects to announce interim clinical data by the end of 2021.
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) announced on June 1, 2021, that CEO Frederic Chereau will participate in virtual fireside chats at two investor conferences. The events include the Jefferies Virtual Healthcare Conference on June 4 at 9:30 AM ET and the JMP Securities Life Sciences Conference on June 16 at 2:00 PM ET. Interested parties can access live webcasts through the Investors section of the company's website. LogicBio focuses on pioneering gene delivery and editing platforms to address rare diseases, utilizing innovative technologies like GeneRide™ and sAAVy™.
LogicBio Therapeutics (Nasdaq: LOGC) announced the promotion of Dr. Daniel Gruskin to Chief Medical Officer and the appointment of Dr. Stephen Boyer as Vice President of Regulatory and Quality Affairs, along with Dr. Peter Pechan as Vice President of Gene Therapy. These leadership changes support ongoing advancements in the Phase I/II SUNRISE clinical trial of LB-001, an investigational treatment for methylmalonic acidemia (MMA). The new appointments come amidst recent collaborations with Daiichi Sankyo and CANbridge Pharmaceuticals.
LogicBio Therapeutics (Nasdaq: LOGC) reported its first-quarter financial results for 2021, showing a net loss of $10.3 million or $0.32 per share, compared to a loss of $9.5 million or $0.41 per share in Q1 2020. R&D expenses decreased to $6.4 million from $7.2 million, while G&A expenses rose to $4.1 million. The company had cash reserves of $63.9 million and expects this to sustain operations for at least the next 12 months. Anticipated milestones include patient enrollment in the SUNRISE trial for LB-001 by mid-2021 and interim data by year-end.
LogicBio Therapeutics (Nasdaq: LOGC) announced key appointments on May 10, 2021, with Andrea Paul as general counsel and corporate secretary, effective May 17, and Janice Olson as senior vice president of strategy and portfolio management, effective June 7. Both bring extensive experience in pharmaceutical and biotechnology sectors. The company also reported the resignation of COO Kyle Chiang effective May 28. CEO Frederic Chereau expressed optimism about the new appointments and their potential to enhance LogicBio's gene delivery and gene editing platforms amid ongoing collaborations with Daiichi Sankyo and CANbridge Pharmaceuticals.
LogicBio Therapeutics (Nasdaq:LOGC) announced preclinical data presentations at the upcoming 24th Annual ASGCT Virtual Meeting from May 11-14, 2021. Key findings include the oral presentation by Dr. Jing Liao on the sL65 AAV capsid, which demonstrated high potency in humanized mice and non-human primates for liver disease treatment. Additionally, data on the GeneRide platform showed improved outcomes for methylmalonic acidemia and significantly reduced bilirubin levels in Crigler-Najjar syndrome in mouse models. These presentations highlight the potential of LogicBio's genetic therapies.
LogicBio Therapeutics (Nasdaq:LOGC) announced results from a retrospective study on severe methylmalonic acidemia (MMA), a rare genetic disorder. Conducted at the ACMG Annual Clinical Genetics Meeting, the study included 18 pediatric patients, demonstrating a significant post-liver transplantation decrease in methylmalonic acid levels, indicating improved metabolic stability. However, no substantial differences were observed in emergency room visits or hospitalizations before and after transplantation. The findings will inform the clinical trial design for LB-001, a program targeting MMA.